Secukinumab in psoriasis patients with prior ustekinumab treatment: Results of a single- center experience Ting-Shun Wang, Chih-Chieh Chan, Hsien-Yi Chiu,

Slides:

Advertisements

Similar presentations

Individualized Medicine from Prewomb to Tomb Eric J. Topol Cell Volume 157, Issue 1, Pages (March 2014) DOI: /j.cell Copyright.

Advertisements

Two views of brain function Marcus E. Raichle Trends in Cognitive Sciences Volume 14, Issue 4, Pages (April 2010) DOI: /j.tics

2015 Alzheimer's disease facts and figures Alzheimer's & Dementia: The Journal of the Alzheimer's Association Volume 11, Issue 3, Pages (March.

2002 Air Medical Transport Industry Awards Air Medical Journal Volume 22, Issue 2, Pages (March 2003) DOI: /S X(03) Copyright.

A rare complication of Meckel's diverticulum: A fistula between Meckel's diverticulum and the appendix Ping-Fu Yang, Chau-Yun Chen, Fang-Jung Yu, Sheau-Fang.

Keratoacanthoma centrifugum marginatum—A rare variant of keratoacanthoma: Case report and literature review Chao Shiang Sung, Fu Chen Chuang, Ji Chen.

Volume 33, Issue 4, Pages (December 2015)

Colloquium on Therapy of Right Heart Failure

Evaluation of some chronical diseases in etiopathogenesis of demodicosis Zeynep Tas Cengiz, Hatice Uce Ozkol, Yunus Emre Beyhan, Murat Ozturk, Hasan Yilmaz

Volume 33, Issue 1, Pages (March 2015)

Efficacy and safety of a single treatment using a 10,600-nm carbon dioxide fractional laser for mild-to-moderate atrophic acne scars in Asian skin Pa-Fan.

Palmoplantar pustulosis with severe psoriatic nail dystrophy in a patient receiving etanercept for treatment of ankylosing spondylitis Sheng-Pei Wang

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial Diamant.

Volume 33, Issue 3, Pages (September 2015)

Volume 31, Issue 2, Pages (June 2013)

Bullous pyoderma gangrenosum induced by a local injection of guadecitabine in a patient with acute myeloid leukemia Yi-Chun Hou Dermatologica Sinica

All-Cause and Cause-Specific Mortality in Patients with Psoriasis in Taiwan: A Nationwide Population-Based Study Meng-Sui Lee, Yi-Chun Yeh, Yun-Ting.

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to- severe plaque psoriasis up to 1 year: Results from the CLEAR study

Stephanie J. Lee, Loretta A. Williams

Volume 80, Issue 4, Pages (August 2011)

Effusive Tuberculous Pericarditis

Acute Paralysis in a Uremic Patient

Repigmentation and new growth of hairs after anti–interleukin-17 therapy with secukinumab for psoriasis Franco Rongioletti, MD, Cristina Mugheddu, MD,

Perspectives in Psoriasis: Assessing Treatment Efficacy—Which Measures, What Do They Tell Us?

Clinical Application of Therapies Targeting VEGF

Diffuse depigmentation in a patient with chronic myeloid leukemia

Covering the Cover Gastroenterology

The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study Hsien-Yi Chiu, MD, Tsen-Fang.

Ira J. Fox, Stephen C. Strom Gastroenterology

The Case ∣ Ascites with oliguric acute renal failure

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial Diamant.

Acute Respiratory Distress Syndrome With and Without Extracorporeal Membrane Oxygenation: A Score Matched Study Hsiao-Chi Tsai, MD, Chih-Hsiang Chang,

Hypertensive Disorders in Pregnancy and Subsequent Diabetes Mellitus: A Retrospective Cohort Study I-Kuan Wang, MD, I-Ju Tsai, MS, Pei-Chun Chen, PhD,

Yung-Chih Chen, MD, Wan-Ting Chiu, MD, Mai-Szu Wu, MD

Virologic Response to Therapy Increases Health-Related Quality of Life for Patients With Chronic Hepatitis B Jeong Han Kim, So Young Kwon, Young Sok.

Loss of efficacy of secukinumab for psoriasis at 24 to 32 weeks

Comparable Long-term Outcomes of 1-Minute vs 5-Minute Endoscopic Papillary Balloon Dilation for Bile Duct Stones Yu-Ting Kuo, Hsiu-Po Wang, Chi-Yang.

Juan A. Crestanello, MD, Richard C. Daly, MD

Objective Palliative Prognostic Score Among Patients With Advanced Cancer Yen-Ting Chen, MD, Chih-Te Ho, MD, Hua-Shai Hsu, MD, Po-Tsung Huang, MD, Chin-Yu.

Volume 26, Issue 2, Pages (February 2018)

Wen-Ling Lee, M. D. , Wei-Min Liu, M. D. , Jong-Ling Fuh, M. D

A Phase III, Randomized, Controlled Trial of the Fully Human IL-12/23 mAb Briakinumab in Moderate-to-Severe Psoriasis Kenneth B. Gordon, Richard G. Langley,

Stephanie J. Lee, Loretta A. Williams

Severe Constipation Clinical Gastroenterology and Hepatology

Steroid-free maintenance immunosuppression in kidney transplantation: is it time to consider it as a standard therapy? Fu L. Luan, Diane E. Steffick,

Efficacy and Safety of Systemic Long-Term Treatments for Moderate-to-Severe Psoriasis: A Systematic Review and Meta-Analysis Alexander Nast, Anja Jacobs,

Chih-Ping Chen, M. D. , Shuan-Pei Lin, M. D. , Fuu-Jen Tsai, M. D

Calcified amorphous tumor of left atrium

A new era in phosphate binder therapy: What are the options?

Barrie R. Cassileth, PhD, Andrew J. Vickers, PhD

Cost-Effectiveness of Biologic Agents in the Treatment of Moderate-to-Severe Psoriasis: A Brazilian Public Health Service Perspective Bruno Salgado Riveros,

The impact of smoking in primary spontaneous pneumothorax

Significant elevation of plasma matrix metalloproteinase-9 level and its ratio to matrix metalloproteinase-2 in patients with pelvic inflammatory disease

Prospective randomized study of individual and group psychotherapy versus controls in recipients of renal transplants1 Lyndsay S. Baines, John T. Joseph,

How Do New Data from Clinical Trials Allow Us to Optimise the Assessment and Treatment of Patients with Benign Prostatic Hyperplasia? Vincenzo Mirone

High-Density Lipoprotein Cholesterol Function Improves after Successful Treatment of Psoriasis: A Step Forward in the Right Direction Nehal N. Mehta,

Arlene Chan, Marc Buyse, Bin Yao The Lancet Oncology

HLA-C*06:02 Allele and Response to IL-12/23 Inhibition: Results from the Ustekinumab Phase 3 Psoriasis Program Katherine Li, C. Chris Huang, Bruce Randazzo,

Organization news Archives of Physical Medicine and Rehabilitation

In This Issue Molecular Therapy Volume 16, Issue 4, (April 2008)

Value in Health Regional Issues

Ustekinumab treatment is associated with decreased systemic and vascular inflammation in patients with moderate-to-severe psoriasis: Feasibility study.

Pityriasis rubra pilaris with polyarthritis treated with adalimumab

Patrick Yachimski, William P. Puricelli, Norman S. Nishioka

Tamar Nijsten, Diane Whalley, Joel Gelfand, David Margolis, Stephen P

Markedly elevated plasma myeloperoxidase protein in patients with pelvic inflammatory disease who have A allele myeloperoxidase gene polymorphism Shun-An.

Tofacitinib therapy for children with severe alopecia areata

Volume 4, Issue 3, Pages (March 2018)

Pleurodesis for primary spontaneous pneumothorax – Authors' reply

Brodalumab in the treatment of moderate to severe psoriasis in patients when previous anti-interleukin 17A therapies have failed Grace Kimmel, MD, Margot.

Presentation transcript:

Secukinumab in psoriasis patients with prior ustekinumab treatment: Results of a single- center experience Ting-Shun Wang, Chih-Chieh Chan, Hsien-Yi Chiu, Tsen-Fang Tsai Dermatologica Sinica Volume 35, Issue 1, Pages 25-29 (March 2017) DOI: 10.1016/j.dsi.2016.09.005 Copyright © 2016 Terms and Conditions

Figure 1 PASI trends of ustekinumab versus secukinumab. (A) Trend of PASI score of ustekinumab therapy. (B) Trend of PASI score of secukinumab therapy. PASI=Psoriasis Area Severity Index. Dermatologica Sinica 2017 35, 25-29DOI: (10.1016/j.dsi.2016.09.005) Copyright © 2016 Terms and Conditions